WO2009136884A3 - Metformin-pioglitazone formulation with antihyperglycemic effects - Google Patents

Metformin-pioglitazone formulation with antihyperglycemic effects Download PDF

Info

Publication number
WO2009136884A3
WO2009136884A3 PCT/TR2009/000057 TR2009000057W WO2009136884A3 WO 2009136884 A3 WO2009136884 A3 WO 2009136884A3 TR 2009000057 W TR2009000057 W TR 2009000057W WO 2009136884 A3 WO2009136884 A3 WO 2009136884A3
Authority
WO
WIPO (PCT)
Prior art keywords
pioglitazone
metformin
micronized
acceptable salts
diabetes treatment
Prior art date
Application number
PCT/TR2009/000057
Other languages
French (fr)
Other versions
WO2009136884A2 (en
Inventor
Alper Mahrebel
Serap Odabasi
Muge Ozcan
Aylin Yagiz
Meryem Ulku Guler
Sezen Kandemirer
Original Assignee
Bilim Ilac Sanayi Ticaret A.S.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bilim Ilac Sanayi Ticaret A.S. filed Critical Bilim Ilac Sanayi Ticaret A.S.
Publication of WO2009136884A2 publication Critical patent/WO2009136884A2/en
Publication of WO2009136884A3 publication Critical patent/WO2009136884A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles

Abstract

This invention relates to pharmaceutical products and manufacturing process which includes Metformin or pharmaceutical acceptable salts and especially hydrochloride salts with micronized Pioglitazone or it's pharmaceutical acceptable salts and especially hydrochloride salts. The oral solid dosage form compound which is developed by this invention includes one or more filling, binder, disintegrant and/or lubricant with meformin and micronized pioglitazone, which is manufactured by wet granulation in same carrier for diabetes treatment and especially Type-2 diabetes treatment.
PCT/TR2009/000057 2008-05-06 2009-05-05 Metformin-pioglitazone formulation with antihyperglycemic effects WO2009136884A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2008/03177 2008-05-06
TR2008/03177A TR200803177A2 (en) 2008-05-06 2008-05-06 Metformin - pioglitazone formulation with antihyperglycemic action.

Publications (2)

Publication Number Publication Date
WO2009136884A2 WO2009136884A2 (en) 2009-11-12
WO2009136884A3 true WO2009136884A3 (en) 2009-12-23

Family

ID=41152147

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2009/000057 WO2009136884A2 (en) 2008-05-06 2009-05-05 Metformin-pioglitazone formulation with antihyperglycemic effects

Country Status (2)

Country Link
TR (1) TR200803177A2 (en)
WO (1) WO2009136884A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2441442A1 (en) 2010-10-08 2012-04-18 LEK Pharmaceuticals d.d. A pharmaceutical composition comprising a thiazolidinedione
WO2014016371A1 (en) * 2012-07-27 2014-01-30 Ratiopharm Gmbh Micronized aleglitazar
TR201620309A2 (en) * 2016-12-30 2018-07-23 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical compositions of metformin hydrochloride and pioglitazone hydrochloride
CN115804770B (en) * 2022-11-16 2024-04-02 安徽杰玺医药有限公司 Pharmaceutical preparation containing metformin hydrochloride and pioglitazone hydrochloride and preparation method thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001035941A2 (en) * 1999-11-16 2001-05-25 Smithkline Beecham P.L.C. Novel composition based on a thiazolidinedione and metformin and use
US20050131027A1 (en) * 2002-03-21 2005-06-16 Guy Samburski Fine particle size pioglitazone
EP1552832A1 (en) * 2002-07-11 2005-07-13 Takeda Pharmaceutical Company Limited Process for producing coated preparation
EP1561472A1 (en) * 2002-10-07 2005-08-10 Takeda Pharmaceutical Company Limited Solid preparation
EP1738754A1 (en) * 2004-04-14 2007-01-03 Takeda Pharmaceutical Company Limited Solid pharmaceutical preparation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001035941A2 (en) * 1999-11-16 2001-05-25 Smithkline Beecham P.L.C. Novel composition based on a thiazolidinedione and metformin and use
US20050131027A1 (en) * 2002-03-21 2005-06-16 Guy Samburski Fine particle size pioglitazone
EP1552832A1 (en) * 2002-07-11 2005-07-13 Takeda Pharmaceutical Company Limited Process for producing coated preparation
EP1561472A1 (en) * 2002-10-07 2005-08-10 Takeda Pharmaceutical Company Limited Solid preparation
EP1738754A1 (en) * 2004-04-14 2007-01-03 Takeda Pharmaceutical Company Limited Solid pharmaceutical preparation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KARIM AZIZ ET AL: "Oral antidiabetic drugs: Effect of food on absorption of pioglitazone and metformin from a fixed-dose combination tablet", JOURNAL OF CLINICAL PHARMACOLOGY, vol. 47, no. 1, January 2007 (2007-01-01), pages 48 - 55, XP009124359, ISSN: 0091-2700 *

Also Published As

Publication number Publication date
WO2009136884A2 (en) 2009-11-12
TR200803177A2 (en) 2009-11-23

Similar Documents

Publication Publication Date Title
IL233677A (en) Substituted benzisoxazole aminopyrazolo-pyrimidine compounds, pharmaceutical compositions comprising them and use of the compounds for the manufacture of medicaments
IL250858B (en) A tetracycline compound, a pharmaceutical composition comprising the tetracycline compound, and the tetracycline compound or the pharmaceutical composition for treating a tetracycline responsive state
WO2007082808A3 (en) Thiazoles as 11 beta-hsd1 inhibitors
TN2009000317A1 (en) Solid preparation comprising alogliptin and pioglitazone
IL225198A (en) Aminotetrahydropyran compounds, pharmaceutical compositions comprising the same and the use thereof for the treatment of diabetes
WO2007096151A3 (en) Inhibitors of p38-kinase for treatment of pulmonary hypertension
WO2008037716A3 (en) Pharmaceutical compositions comprising nilotinib or its salt
GEP20135803B (en) Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives
AP2303A (en) d-Crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it.
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors
AP2006003521A0 (en) Y-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it.
WO2006011159A3 (en) Stabilized pharmaceutical composition containing rabeprazole sodium with improved bioavailability
CL2007001778A1 (en) COMPOUNDS DERIVED FROM 2-PIRAZINACARBOXAMIDA, ANTAGONISTS / SELECTIVE INVESTED AGONISTS OF CB1; PREPARATION PROCESS; PHARMACEUTICAL COMPOSITIONS; AND USE FOR THE TREATMENT AND / OR PROFILAXIS OF FOOD INGESTION DISORDERS, TYPE II AND A DIABETES
WO2008062273A8 (en) Solid oral dosage form having antidiabetic drug combination
HK1095146A1 (en) Aminopyrimidine compounds and their salts, process for preparation and pharmaceutical use thereof
IL185277A0 (en) Pharmaceutical compositions containing roflumilast for the treatment of diabetes
CA2725933A1 (en) Drug combinations comprising a dgat inhibitor and a ppar-agonist
BRPI0814666A2 (en) pharmaceutical composition for oral administration, use of a formulation. process for preparing a solid dosage form, and, solid dosage form
BRPI0807285A2 (en) "COMPOSITION, METHOD FOR PREPARING PHARMACEUTICAL COMPOSITION, UNIT FORM OF DOSAGE, METHOD FOR ADMINISTRATING A BIOLOGICAL ACTIVE AGENT NEEDING THE AGENT, METHOD FOR INCREASING BIODISPONABILITY FOR PREPARING AN AGENT OF COMPOSITION"
WO2007090661A3 (en) Active substance combination comprising azolylcarbinol compounds
CL2008000750A1 (en) METHOD FOR THE ADMINISTRATION OF A WEEKLY DOSE OF 2- [6- (3-AMINO-PIPERIDIN-1-IL) 3-METHYL-2,4 DIOXO-3,4 DIHYDRO-2H-PIRIMIDIN-1-IL METIL] -4 FLUORO-BENZONITRILE; PHARMACEUTICAL COMPOSITION OF AN INDIVIDUAL DOSAGE FORM OF SUCH COMPOUND; AND HIS
SG151172A1 (en) 1,2,4,5-tetrahydro-3h-benzazepine compounds, a process for their preparation and pharmaceutical compositions containing them
WO2006134021A3 (en) Process for preparing tiotropium salts, tiotropium salts as such and pharmaceutical compositions thereof
WO2008151811A3 (en) Process for the preparation of a medicament comprising vardenafil hydrochloride trihydrate
WO2009120389A8 (en) Oral and injectable formulations of tetracycline compounds

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09742953

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09742953

Country of ref document: EP

Kind code of ref document: A2